Respiratory viral infections in transplant and oncology patients

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 395-412

  Kumar, Deepali ^a   Humar, Atul ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Hematopoietic stem cell transplant; Influenza; Solid organ transplant

Indexed keywords

ALN RSV 01; AMANTADINE; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CORTICOSTEROID; IMMUNOGLOBULIN; INFLUENZA VACCINE; MOTAVIZUMAB; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; PLECONARIL; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RIBAVIRIN; RIMANTADINE; STEROID; VIRUS DNA; ZANAMIVIR;

ACUTE GRAFT REJECTION; ADENOVIRUS INFECTION; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HUMAN; HUMAN METAPNEUMOVIRUS; HYPOCALCEMIA; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION CONTROL; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); KI POLYOMAVIRUS; LABORATORY TEST; MALIGNANT NEOPLASTIC DISEASE; METAPNEUMOVIRUS INFECTION; MYELOABLATIVE CONDITIONING; NONHUMAN; NONMYELOABLATIVE CONDITIONING; ORGAN TRANSPLANTATION; PARAINFLUENZA VIRUS; PARAINFLUENZA VIRUS INFECTION; PARVOVIRUS INFECTION; PATHOGENESIS; POLYOMA VIRUS; POLYOMAVIRUS INFECTION; PREVALENCE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY VIRUS; REVIEW; RHINOVIRUS INFECTION; SEVERE ACUTE RESPIRATORY SYNDROME; THORAX RADIOGRAPHY; VIRAL RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; VIRUS STRAIN; VIRUS TRANSMISSION; WU POLYOMAVIRUS;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; RESPIRATORY TRACT INFECTIONS; TRANSPLANTATION; VIRUS DISEASES; VIRUSES;

EID: 77952723344     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.007     Document Type: Review

References (133)

1. Siegel J.D., Rhinehart E., Jackson M., et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007, 35:S65.
2. Kuypers J., Campbell A.P., Cent A., et al. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009, 11(4):298-303.
3. Ljungman P., Ward K.N., Crooks B.N., et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001, 28:479.
4. Martino R., Porras R.P., Rabella N., et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005, 11:781.
5. Peck A.J., Englund J.A., Kuypers J., et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood 2007, 110:1681.
6. Chemaly R.F., Ghosh S., Bodey G.P., et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006, 85:278.
7. Schiffer J.T., Kirby K., Sandmaier B., et al. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009, 94:1101.
8. Martino R., Pinana J.L., Parody R., et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009, 44(11):749-756.
9. Bonatti H., Pruett T.L., Brandacher G., et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc 2009, 41:371.
10. Garbino J., Soccal P.M., Aubert J.D., et al. Respiratory viruses in bronchoalveolar lavage: a hospital-based cohort study in adults. Thorax 2009, 64:399.
11. Gottlieb J., Schulz T.F., Welte T., et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009, 87:1530.
12. Lopez-Medrano F., Aguado J.M., Lizasoain M., et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007, 84:851.
13. Milstone A.P., Brumble L.M., Barnes J., et al. A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J 2006, 28:131.
14. Franquet T., Rodriguez S., Martino R., et al. Thin-section CT findings in hematopoietic stem cell transplantation recipients with respiratory virus pneumonia. AJR Am J Roentgenol 2006, 187:1085.
15. Marchiori E., Escuissato D.L., Gasparetto T.D., et al. Crazy-paving patterns on high-resolution CT scans in patients with pulmonary complications after hematopoietic stem cell transplantation. Korean J Radiol 2009, 10:21.
16. van Kraaij M.G., van Elden L.J., van Loon A.M., et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis 2005, 40:662.
17. Kumar D., Humar A. Pandemic influenza and its implications for transplantation. Am J Transplant 2006, 6:1512.
18. Mahony J.B. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008, 21:716.
19. Fox J.D. Nucleic acid amplification tests for detection of respiratory viruses. J Clin Virol 2007, 40(Suppl 1):S15.
20. Ison M.G., Hayden F.G. Viral infections in immunocompromised patients: what's new with respiratory viruses?. Curr Opin Infect Dis 2002, 15:355.
21. Vilchez R.A., McCurry K., Dauber J., et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002, 2:287.
22. Ljungman P., Andersson J., Aschan J., et al. Influenza A in immunocompromised patients. Clin Infect Dis 1993, 17:244.
23. Nichols W.G., Guthrie K.A., Corey L., et al. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004, 39:1300.
24. Khanna N., Steffen I., Studt J.D., et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009, 11:100.
25. Tasian S.K., Park J.R., Martin E.T., et al. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer 2008, 50:983.
26. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998, 352:1877.
27. Hayden F.G., Osterhaus A.D., Treanor J.J., et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997, 337:874.
28. Makela M.J., Pauksens K., Rostila T., et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000, 40:42.
29. Johny A.A., Clark A., Price N., et al. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 29:113.
30. Medeiros R., Rameix-Welti M.A., Lorin V., et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther 2007, 12:571.
31. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008, 52:3284.
32. Monto A.S. Antivirals and influenza: frequency of resistance. Pediatr Infect Dis J 2008, 27:S110.
33. Ilyushina N.A., Hay A., Yilmaz N., et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008, 52:3889.
34. Smee D.F., Hurst B.L., Wong M.H., et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009, 53:2120.
35. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2004, 4(Suppl 10):160.
36. Ljungman P., Avetisyan G. Influenza vaccination in hematopoietic SCT recipients. Bone Marrow Transplant 2008, 42:637.
37. Ljungman P., Engelhard D., de la Camara R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005, 35:737.
38. Elizaga J., Olavarria E., Apperley J., et al. Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001, 32:413.
39. Nichols W.G., Erdman D.D., Han A., et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004, 10:58.
40. Cortez K.J., Erdman D.D., Peret T.C., et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001, 184:1093.
41. Hohenthal U., Nikoskelainen J., Vainionpaa R., et al. Parainfluenza virus type 3 infections in a hematology unit. Bone Marrow Transplant 2001, 27:295.
42. Jalal H., Bibby D.F., Bennett J., et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol 2007, 45:1690.
43. Piralla A., Percivalle E., Di Cesare-Merlone A., et al. Multicluster nosocomial outbreak of parainfluenza virus type 3 infection in a pediatric oncohematology unit: a phylogenetic study. Haematologica 2009, 94:833.
44. Zambon M., Bull T., Sadler C.J., et al. Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol 1998, 36:2289.
45. Au W.Y., Lie A.K., Cheung R.T., et al. Acute disseminated encephalomyelitis after para-influenza infection post bone marrow transplantation. Leuk Lymphoma 2002, 43:455.
46. Lange T., Franke G., Niederwieser D. Parotitis associated with a parainfluenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation. Leuk Lymphoma 2006, 47:1714.
47. Rodriguez V., Kuehnle I., Heslop H.E., et al. Guillain-Barre syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002, 29:515.
48. Vilchez R.A., Dauber J., McCurry K., et al. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003, 3:116.
49. Ferguson P.E., Sorrell T.C., Bradstock K.F., et al. Parainfluenza virus type 3 pneumonia in bone marrow transplant recipients: multiple small nodules in high-resolution lung computed tomography scans provide a radiological clue to diagnosis. Clin Infect Dis 2009, [Epub ahead of print].
50. Chakrabarti S., Collingham K.E., Holder K., et al. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2001, 28:759.
51. McCurdy L.H., Milstone A., Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant 2003, 22:745.
52. Nichols W.G., Gooley T., Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant 2001, 7(Suppl):11S.
53. Shima T., Yoshimoto G., Nonami A., et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol 2008, 88:336.
54. Wright J.J., O'Driscoll G. Treatment of parainfluenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone. J Heart Lung Transplant 2005, 24:343.
55. El Saleeby C.M., Somes G.W., DeVincenzo J.P., et al. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 2008, 121:235.
56. Sung L., Alonzo T.A., Gerbing R.B., et al. Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008, 51:784.
57. Mahony J., Chong S., Merante F., et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 2007, 45:2965.
58. Boeckh M., Englund J., Li Y., et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007, 44:245.
59. Pelaez A., Lyon G.M., Force S.D., et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 2009, 28:67.
60. Glanville A.R., Scott A.I., Morton J.M., et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005, 24:2114.
61. Chavez-Bueno S., Mejias A., Merryman R.A., et al. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Pediatr Infect Dis J 2007, 26:1089.
62. Michaels M.G., Fonseca-Aten M., Green M., et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant 2009, 13:451.
63. Englund J.A., Boeckh M., Kuypers J., et al. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med 2006, 144:344.
64. Kamboj M., Gerbin M., Huang C.K., et al. Clinical characterization of human metapneumovirus infection among patients with cancer. J Infect 2008, 57:464.
65. Oliveira R., Machado A., Tateno A., et al. Frequency of human metapneumovirus infection in hematopoietic SCT recipients during 3 consecutive years. Bone Marrow Transplant 2008, 42:265.
66. Evashuk K.M., Forgie S.E., Gilmour S., et al. Respiratory failure associated with human metapneumovirus infection in an infant posthepatic transplant. Am J Transplant 2008, 8:1567.
67. Debiaggi M., Canducci F., Sampaolo M., et al. Persistent symptomless human metapneumovirus infection in hematopoietic stem cell transplant recipients. J Infect Dis 2006, 194:474.
68. Gerna G., Vitulo P., Rovida F., et al. Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients. J Med Virol 2006, 78:408.
69. Hopkins P., McNeil K., Kermeen F., et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med 2008, 178:876.
70. Hamelin M.E., Prince G.A., Boivin G. Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection. Antimicrob Agents Chemother 2006, 50:774.
71. Wyde P.R., Chetty S.N., Jewell A.M., et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro. Antiviral Res 2003, 60:51.
72. Wyde P.R., Moylett E.H., Chetty S.N., et al. Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by NMSO3 in tissue culture assays. Antiviral Res 2004, 63:51.
73. Bonney D., Razali H., Turner A., et al. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 2009, 145:667.
74. Raza K., Ismailjee S.B., Crespo M., et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007, 26:862.
75. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early I.V. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant 2008, 41:707.
76. Herfst S., Fouchier R.A. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 2008, 41:49.
77. Herfst S., Schrauwen E.J., de Graaf M., et al. Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine 2008, 26:4224.
78. Garbino J., Crespo S., Aubert J.D., et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection. Clin Infect Dis 2006, 43:1009.
79. Kumar D., Erdman D., Keshavjee S., et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant 2005, 5:2031.
80. Pene F., Merlat A., Vabret A., et al. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003, 37:929.
81. Drosten C., Gunther S., Preiser W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 1967, 348:2003.
82. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1953.
83. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394.
84. Adachi D., Johnson G., Draker R., et al. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. J Virol Methods 2004, 122:29.
85. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289:2801.
86. Chiou H.E., Liu C.L., Buttrey M.J., et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005, 128:263.
87. Knowles S.R., Phillips E.J., Dresser L., et al. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003, 37:1139.
88. Kumar D., Tellier R., Draker R., et al. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant 2003, 3:977.
89. Farcas G.A., Poutanen S.M., Mazzulli T., et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005, 191:193.
90. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008, 21:704.
91. Humar A., Kumar D., Mazzulli T., et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant 2005, 5:2555.
92. McGrath D., Falagas M.E., Freeman R., et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis 1998, 177:459.
93. Michaels M.G., Green M., Wald E.R., et al. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992, 165:170.
94. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. Eur J Clin Microbiol Infect Dis 2004, 23:583.
95. Fox J.D. Respiratory virus surveillance and outbreak investigation. J Clin Virol 2007, 40(Suppl 1):S24.
96. Lion T., Baumgartinger R., Watzinger F., et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003, 102:1114.
97. Hofland C.A., Eron L.J., Washecka R.M. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004, 36:3025.
98. Bordigoni P., Carret A.S., Venard V., et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001, 32:1290.
99. Doan M.L., Mallory G.B., Kaplan S.L., et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007, 26:883.
100. Refaat M., McNamara D., Teuteberg J., et al. Successful cidofovir treatment in an adult heart transplant recipient with severe adenovirus pneumonia. J Heart Lung Transplant 2008, 27:699.
101. Ribaud P., Scieux C., Freymuth F., et al. Successful treatment of adenovirus disease with intravenous cidofovir in an unrelated stem-cell transplant recipient. Clin Infect Dis 1999, 28:690.
102. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134:64.
103. Leen A.M., Christin A., Myers G.D., et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplant. Blood 2009, 114(19):4283-4292.
104. Neofytos D., Ojha A., Mookerjee B., et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007, 13:74.
105. Symeonidis N., Jakubowski A., Pierre-Louis S., et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007, 9:108.
106. Parody R., Rabella N., Martino R., et al. Upper and lower respiratory tract infections by human enterovirus and rhinovirus in adult patients with hematological malignancies. Am J Hematol 2007, 82:807.
107. Gutman J.A., Peck A.J., Kuypers J., et al. Rhinovirus as a cause of fatal lower respiratory tract infection in adult stem cell transplantation patients: a report of two cases. Bone Marrow Transplant 2007, 40:809.
108. Kaiser L., Aubert J.D., Pache J.C., et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006, 174:1392.
109. Gerna G., Piralla A., Rovida F., et al. Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients. J Med Virol 2009, 81:1498.
110. Hayden F.G., Herrington D.T., Coats T.L., et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003, 36:1523.
111. Costa C., Terlizzi M.E., Solidoro P., et al. Detection of parvovirus B19 in the lower respiratory tract. J Clin Virol 2009, 46(2):150-153.
112. Beske F., Modrow S., Sorensen J., et al. Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 40:89.
113. Janner D., Bork J., Baum M., et al. Severe pneumonia after heart transplantation as a result of human parvovirus B19. J Heart Lung Transplant 1994, 13:336.
114. Waldman M., Kopp J.B. Parvovirus-B19-associated complications in renal transplant recipients. Nat Clin Pract Nephrol 2007, 3:540.
115. Allander T. Human bocavirus. J Clin Virol 2008, 41:29.
116. Allander T., Tammi M.T., Eriksson M., et al. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A 2005, 102:12891.
117. Schenk T., Strahm B., Kontny U., et al. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 2007, 13:1425.
118. Kupfer B., Vehreschild J., Cornely O., et al. Severe pneumonia and human bocavirus in adult. Emerg Infect Dis 2006, 12:1614.
119. Miyakis S., van Hal S.J., Barratt J., et al. Absence of human Bocavirus in bronchoalveolar lavage fluid of lung transplant patients. J Clin Virol 2009, 44:179.
120. Kantola K., Hedman L., Allander T., et al. Serodiagnosis of human bocavirus infection. Clin Infect Dis 2008, 46:540.
121. Lindner J., Karalar L., Schimanski S., et al. Clinical and epidemiological aspects of human bocavirus infection. J Clin Virol 2008, 43:391.
122. Bialasiewicz S., Whiley D.M., Lambert S.B., et al. Presence of the newly discovered human polyomaviruses KI and WU in Australian patients with acute respiratory tract infection. J Clin Virol 2008, 41:63.
123. Bialasiewicz S., Whiley D.M., Lambert S.B., et al. A newly reported human polyomavirus, KI virus, is present in the respiratory tract of Australian children. J Clin Virol 2007, 40:15.
124. Gaynor A.M., Nissen M.D., Whiley D.M., et al. Identification of a novel polyomavirus from patients with acute respiratory tract infections. PLoS Pathog 2007, 3:e64.
125. Le B.M., Demertzis L.M., Wu G., et al. Clinical and epidemiologic characterization of WU polyomavirus infection, St. Louis, Missouri. Emerg Infect Dis 2007, 13:1936.
126. Mourez T., Bergeron A., Ribaud P., et al. Polyomaviruses KI and WU in immunocompromised patients with respiratory disease. Emerg Infect Dis 2009, 15:107.
127. Norja P., Ubillos I., Templeton K., et al. No evidence for an association between infections with WU and KI polyomaviruses and respiratory disease. J Clin Virol 2007, 40:307.
128. Bialasiewicz S., Whiley D.M., Lambert S.B., et al. Detection of BK, JC, WU, or KI polyomaviruses in faecal, urine, blood, cerebrospinal fluid and respiratory samples. J Clin Virol 2009, 45:249.
129. Billings J.L., Hertz M.I., Savik K., et al. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant 2002, 21:559.
130. Khalifah A.P., Hachem R.R., Chakinala M.M., et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004, 170:181.
131. Husain S., Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002, 17:310.
132. Ison M.G., Sharma A., Shepard J.A., et al. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008, 27:282.
133. Vu D., Peck A.J., Nichols W.G., et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007, 45:187.